ColonAiQ - DNA-based blood test for early detection of colorectal cancer

The ColonAiQ® test is a non-invasive blood test for the early detection of colorectal cancer. It analyzes cell-free DNA (cfDNA) in the blood and detects biochemical changes that indicate an increased risk of cancer.

Colorectal cancer often remains symptomless for a long time, so early detection is crucial. Colorectal cancer screening is suitable for everyone, women and men, from the age of 45. However, younger people can also be affected, especially with a family history or unhealthy lifestyle habits. If detected early, the chance of a cure is up to 90%.

Colorectal cancer is not noticeable for a long time in most cases. Only changed bowel habits or blood in the stool and abdominal pain can indicate colorectal cancer. If the cancer is already more advanced, weight loss and fatigue can occur. Therefore, it is important to take preventive measures in time.

The test only requires 8 ml of blood and can be performed at any time, without the need for fasting. It is recommended to drink sufficient fluids. A blood transfusion should be avoided for at least one week before the test.

The result will be delivered within 14 working days after collection. The result shows changes in specific genes associated with colorectal cancer. High risk: There is an increased risk of colorectal cancer – a colonoscopy is recommended for clarification. Low risk: No indication of colorectal cancer, but regular screening remains important. If the test result is positive, confirmation by imaging procedures is recommended for a definitive diagnosis. Your doctor will determine the need for further examinations. If the test result is negative, there is a low risk of developing colorectal cancer. The ColonAiQ® test can also be used for early detection of a relapse if the patient was already tested before surgery and had a positive result.

With normal risk, regular repetition every 2 years is recommended. In case of increased risk, more frequent testing may be useful.

Yes, the test can also be used after colorectal cancer treatment to detect possible relapses at an early stage.

The test is not suitable for pregnant women, breastfeeding women, or people with a recent blood transfusion (within one week before testing).

ColonAiQ® offers higher sensitivity (86.1%) and specificity (91.6%) than the FIT test (28.6% sensitivity in early stage) or the tumor marker CEA (16.7% sensitivity). The test should be repeated regularly every 2 years or more frequently if the risk is increased.

Yes, ColonAiQ® is suitable for follow-up care after colorectal cancer treatment to detect a possible recurrence at an early stage. Especially in patients with a previous positive test result, a repeat test can help monitor the course. Regular testing allows tumor-associated DNA changes to be detected early and timely measures to be taken.

The ColonAiQ test was specifically developed to detect colorectal cancer (colon and rectal cancer). However, it is possible that the test also responds to other tumors in the gastrointestinal tract, possibly including tumors in the small intestine. Since the number of such rare tumor types in previous studies was very low, no reliable statement can currently be made about the sensitivity of the test for small intestine cancer. This means: detection would in principle be possible, but is not yet sufficiently scientifically proven. For targeted diagnostics in case of suspected small intestine cancer, additional examinations should therefore be considered.